BXRX - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the Baudax Bio Second Quarter 2020 Financial Results Conference Call. At this time, all participants’ are in a listen-only mode. Later we will conduct the question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded at the company’s request. I would now like to turn the call over to Claudia Styslinger, Investor Relations.

begin. may You

Claudia Styslinger

today discuss thank call and financial joining on am us This Chief President Good Officer; Executive discuss you Baudax conference Ryan joined On ANJESO and remarks, Financial I and provide John Officer; to Claudia XXXX Gerri Officer. an Harlow, financial commercial will far, Gerri the Bio’s overview Chief today's Henwood, is John Chief call, and will morning Styslinger, provide the launch will Ryan thus Lake, Commercial for of and by today’s second results. highlights. some quarter introductory

prepared for for and of Ryan, your the The press second today's detailing available issued we up this from baudaxbio.com. Earlier release call we quarter the page morning, XXXX. the Following Investors Gerri, is News and questions. a our release remarks results will on at financial John website press open our

manufacturers as discussion for list and and our third scale-up is our of and party factors ability of ANJESO, our manufacturing acceptance I'll commercial can supply from statements cause actual materially make upcoming, quantities estimate, process successfully to commercial our maintain that important Harbor our other providers are disruption patients, ANJESO hospital to for quality demand Form all-inclusive. of ANJESO, of satisfy statements to uncertainties in of Any ability and that health are The and risks ANJESO. produce obligation future guarantees such that may this physicians, the of in not are approval in website. our December words on with social the COVID-XX statements such XX, XXXX, forward-looking the begin you information, file Baudax any market date forward-looking various to our statements: care sufficient risks on remind analysis expect, the by by successfully to including we the annual otherwise. supply and or report to statements Bio’s for commercial meaning. identified on undertake certain management's underlying and commercialize conference information forward-looking factors in of of future may provisions materially SEC's not to uncertainties. the of performance expectations economic may, we described involve to expressed factors on account impact could and Form These of XXXX, and medical section forecasts differ to the risk subject from anticipate, or on any believe, the similar that remarks the and Reform any cause including and words ability ANJESO; results risks and August pursuant call, our some make as be ANJESO for XX, we are and will, this and which XX-K outlook. Securities this related Private plan, community, formal differ adverse should, available are on of new or Any consequences actual Commission Act statements on we pandemic, to results to chain, year The following the Before These financial XXXX, the intend fiscal our the of ability Securities is Litigation provide our XX-Q, we on of forward-looking and first including call, the regulatory quarterly call, Exchange events constitute the the call update only and forward-looking ended comments, of ongoing our launch today those and reports provided no Safe formularies;

may results that Gerri pro and project does differ Actual positions preliminary not would purport or materially. Gerri? forma or may operating results I any like to addition, financial over to be turn call to the the is In financial Henwood. unaudited information provided now company. of

Gerri Henwood

joining navigate continuing hope and global We morning, the us today everyone. COVID-XX all are continue to through good to Claudia, healthy ongoing keep you, pandemic. Thank those as safe we and

that second launch first report ANJESO event, and commercial is non-NSAID and the our pain of to ANJESO ANJESO that pandemic that the up alone quarter is a on provides for meloxicam impact for people. with preferential off saw safety once-daily solid shared XXXX is to I'm combination launch the pleased and in management indicated relief only intravenous is Baudax, of plan is NSAID team the executing For hospitals, XX-hours in tolerability. full with injection. or in moderate-to-severe use the pain, adults demonstrated considering our COVID-XX having previously COX-X to analgesics. start the ANJESO the surgeries, other on and elective

a revenue June product like all in and XX We XXX,XXX times. deployed Baudax lines generated in U.S. to As company, care professionals, the net healthcare are reps in sales on thank key across would these in territories who front QX. acute experienced

performing the been have with the received for and clinicians We positive reception product ANJESO thus expected that patients. of as is from far, feedback have pleased

are discuss moderate-to-severe Before advancement from the landscape ongoing highlights pain thrilled of a marks say over I for I'll the to be to to our the few I the ANJESO managing acute non-opioid John. in turn pain. potential launch, novel a midst the call we epidemic, call would offer in impact launch with treatment just currently pass to With opioid With to paradigm. major of national option that to the a John still able to therapeutic like more the the treatment that, a meaningfully nation

John Harlow

ANJESO efforts. commercialization the estimate uncertainties pandemic. impacting of recovery, the commercialize the QX and has you, positive in with outbreaks the regional early clinicians which positive, have recent that In a the by continued on pandemic we moment. Even activities efforts from been COVID-XX our Thank Due the this impacted impact been feedback launch and to are to full launch I'll to cannot and critical our early highlight many feedback, accomplished date, we Gerri.

early distributors. acute encouraged an product However, signals the experienced adequate we positive by sales deploying wholesalers are care while team, including and ensuring at availability very specialty

feedback purchased ANJESO using demand from of surgery, are pain pain in process, our we from range nonsurgical delays the XX% medical signal. June, of ambulatory and users early hearing Vizient’s reordering. they XX% appears provides acute The and early positive providers, known care group Following scheduled agreement commercial one U.S. this into diverse management team only terms to is and COVID-XX of reorders have It care care very talked surgical specialist, not providers. to in outside-in On general have to who based early with is clinical by to In We academic novel a of formulary in Several meetings. non-opioid savings an the the members call, of GPO one variety have tried XX% begun more from membership the multiple anesthesiologists promising of early placement. see of launch works as ANJESO, out moderate-to-severe predominantly orthopedics of impacted a early wide be for interventional patients, from building Vizient, in also launch review into we our has in the been somewhat we providers July, full wide a the than Vizient through includes experience, entered our analgesics the in and setting. of nation's but we organizations early nation's still centers, while on approach as playing procedures reordered indicator enhanced usage the coming a account parallel, formulary with positive more largest and acute purchasing outpatient about last which and that with formulary that an see times. the agreement than

X with in and additional approval landscape top pleased in sets we signed of IDNs, volume GPO nationwide. can parties agreements the Also purchase will complete usage. In these with We at continues and or value IDNs, standing in annual formularies our more This process are in potential coming early additional the additional advocacy – regional follow July, the is inclusion for country. We're our a with over agreements as and believe our early believe working we for that incredibly agreement reimbursement of planned. agreement surgical work in the GPOs proceeding with of other as doors the provide. delivery to as be addition build that are they arenas top networks, to the sophisticated the months. We ANJESO that for IDN ANJESO order the also working to GPOs coming team the purchasing the signs direct the represent months. are agreements sets with We some Vizient national in in and positive pleased integrated entry opens the billion the and three than to stage one into

outpatient main at Let product commercial. usage: Medicare for us two and look the groups payer

that unique for outpatient July secured For product. Medicare, ANJESO pass-through C-Code provides patients access facilities became a and we were effective status on build X. use to and traditional for eligible the to Medicare for separately This granted

we'll C-Code. recently JXXXX for new on replace issued that milestone and J-Code, previously CMS. important new achieved October establishment the ANJESO XXXX, the was by was Another the J-Code of X, permanent effect will The take

Advantage, insurance physician Medicare, and of the COVID-XX and ANJESO’s J-Code, commercial consistent access surgery in the With customers to making limited for Medicaid ability will simplifies departments, use feedback, hospital with access face has plans. it to enhance offices submission These have outpatient the the in accounts of ANJESO been the our centers and standardizes code all early marketplace, steps ambulatory further and across ANJESO. to that U.S. one launch Medicare positive will easier payment Even because pandemic. face claims

shift customers. would of live virtual in monitor we closely many we've the outbreaks. will interaction to face. with interactions we ways customers face continue have ways, virtual engaging been new different continue to adapted or increase and whether June seen And to COVID team hotspots The it engaging to potential has percentage regional interactions with July as the of from be with to to versus this However,

the restrictive in Northeast become more it As open July. in very June, was has an example where late

formulary the continue formulary; ANJESO many and said have will review customers several accounts to reordering working team To-date, on through XX over nimble routinely. have engaged as that And placed product. our process. now and I’ve shifts. have we So experience the on early remain accounts as We in more landscape we that be have driving advocacy, access building have appropriately accounts before, we the focused ordered

experienced the making I'll review until call the I'm later access. some gaining forward over financial that, product With our faster, have continue pursue willing those proud of year, move while in accounts to accounts formulary highlights. new the to Although additional turn Ryan? out Ryan to pushed team are pivoting to decision to progress and that

Ryan Lake

results, financial I'll the Thanks, John. review Since XX-Q Form and we some issued a this of just release full our outlining press highlights. morning earlier key our

As million. XX, we and of equivalents cash XXXX, approximately of cash had June $XX.X

certain XXXX, and First, the fixed the supply of the the June million second FDA and sales incurred quality ANJESO was following quarter included in of for sales ended units were was are product costs. during costs, Certain XX, cost XXXX. XXXX prior XX, revenue second June financial full product in Cost June with revenue consisted period. recognized during product not in for chain $X.X XXXX. second results. expense, quarter the and including revenues months There to recognized associated of February were royalty three costs approval the during ANJESO manufacturing ANJESO no commercial the three of product ended quarter months therefore and of Net launch as of the $XXX,XXX, costs

of to expect sales deplete inventory ended of XX, prior our initial pre-approval compared Research was were second a larger three for decrease for new million, of period, cost as to a months $X.X for increase No million. the expenses we year inventory the the suite June manufacturing development expensed $X.X not the levels. cost million and sales XXXX. validate quarter during same and $X.X recorded build We period,

costs $X.X million personnel and for the R&D decrease of $X.X in manufacturing from costs costs Excluding million second pre-commercialization primarily second associated recategorized were quarter our of an $X.X with a allocated overhead decreased affairs expenses million expenses for million of medical expenses with million as the related support of expenses ANJESO to for million, launch XXXX, $X.X we or supply a the and to decrease and the same of commercial administrative restructuring prior regulatory, initiative compared $X.X and the $X.X certain chain, strategic in resulting Selling, year a general ANJESO. quarter associated of $XX.X increase of period, clinical recorded during quality and million.

increased months $X.X ended and million $X.X of increased second expenses affairs marketing regulatory the connection recorded administrative of functions launch SG&A expenses three million $X for including which in the of $X.X had of personnel prior $X.X of medical and recorded June million costs strategic to three for million. support associated million $X.X selling Selling and XXXX, expenses of $X.X the and ANJESO. personnel and increased the June due costs was expenses Excluding our XXXX during million expense $X.X which million research commercial increased period. due and XX, increased primarily ended primarily costs General million to half marketing the the within quarter restructuring increased commercial to year with in over previously with been months attributed XX, XXXX of development of initiative costs, due to

depreciation, in changes to or in including non-cash net of or share. compares changes $XX.X value million valuations, $X.XX of For million warrant $XX.X of the June associated XXXX. XX, non-cash charges per with million, ended stock-based $XX.X second contingent interest Baudax and were $X.XX compensation, XXXX, of for consideration. per non-cash the loss, three amortization, quarter loss net expense, The million of charges of $XX.X This a a fair months reported share

ended build million $XX.X XXXX, to cash the of million cash ANJESO. adjustments based in the related was for For $X.X there with months inventory additional expenses capital and June primarily three associated XX, use working an of

Turning the now months to six financials.

months ended U.S. XX, during revenue million, ended net to no the For six XXXX. $X.X was revenue sales June was June months six XXXX, recognized XX, ANJESO product in the product of the There related

are ANJESO approval XXXX For units FDA ended months XX, were sales of included of the manufacturing and costs June with sales the incurred during February revenue quality fixed costs. of and product the of in was as and therefore in months costs, including ANJESO million XXXX, chain Certain prior consisted recognized royalty XXXX, period. cost associated supply not to certain June during six XX, of cost product of $X.X expense ended six costs and the the ANJESO

new the during inventory sales XX, We a cost were six inventory build not of the of cost suite expect to our deplete recorded manufacturing and we June larger months initial XXXX. validate levels. for sales as increase pre-approval No period, expensed ended

decrease ended $XX.X months XX, expenses XX, For to the million XXXX, June $X.X $XX.X were R&D six million. million, six ended June compared XXXX, the a months for of

the research ANJESO the resulting pre-commercialization million support and restructuring of Excluding related $X.X pipeline decrease as $X.X personnel strategic manufacturing with and ended $X.X million ANJESO. and months $X.X costs supply June quality associated in decreased commercial and and for re-allocated development affairs for in costs with launch development costs our XX, million costs in from initiative expenses a million, a decrease $X.X XXXX, recorded six regulatory, of in primarily expenses a million clinical medical overhead other to associated the we chain, of the of products of of decrease

compared to were XX, year an increase six $XX.X of million, period, months $XX.X $X expenses the same XXXX, prior June million. million the SG&A ended For for

in million to of and and costs the medical marketing of $X.X recorded increased to months expense the been ANJESO. million development costs XX, and due marketing connection increased six increased million expenses and which primarily for recorded regulatory half general the strategic our year increased $XX.X initiative with million personnel with million. of $X.X of XXXX due launch months in costs expenses increased prior expenses in to $X.X of for six was selling, ended General associated June Selling administrative commercial had XXXX, primarily months XXXX functions selling period. support six June $X.X the personnel XX, the of of million ended ended commercial June increased $X.X due million primarily research XX, administrative costs and and restructuring million of and Excluding increased $X.X attributed over $X.X within to the affairs previously which including million, $X.X expenses

$X.X to company costs of million public an prior combined our costs Pharma. Recro the from the increased our historical year separation approximately financial in the portion prior allocated costs addition, In represent as statements

to reported XX, $XX.X million The expense, depreciation, were interest net changes consideration. for in associated and in charges back fair loss, per Baudax June net $XX.X non-cash million of the with Gerri? or stock-based for closing Gerri compensation, $X.XX six non-cash compares including loss charges million the value non-cash a now share. warrant XXXX, of comments. will valuations, changes of approximately a turn $XX.X This I comparable in the call of contingent amortization, months period $XX.X per or share $X.XX million, For XXXX. ended of to

Gerri Henwood

that inform highlight ASC includes Phase meeting. of after in like These this Colon new administered as XXXX Rectal well earlier upon wide and the findings function Ryan use Surgeons settings, are data and virtual to American in is ever-growing allow early of statistically education nine significant first and mention we reorders an These ANJESO look and reductions time the with closing, the clinical the where colorectal recovery The part believe of of continue and our off feedback recently are ahead. through ongoing across the other to quarters Annual the ANJESO of to hospital to a physician commercial months launch, positive we to the encouraged laying ANJESO hospital will and this One strong uptick, we ANJESO further ultimately and call surgery I'll I'd into the the we you And the from will months you, expanded poster work we commercial continue drive trial surgical and and as reinforces during We and keeping as are IDNs, for for adoption XXXX. Society key bowel products when data leads the which start. Thank a availability what launch turn data, initiatives highly because utility the six In GPOs, ANJESO. forward at presented prior is physicians. and is launches sales support study formularies, ANJESO by usage, a to to get updated use we of body surgery. as from as opioid believe supporting in to to they early bricks of build ongoing the to patients of IIIb questions. of of operator to of variety data that we of preoperatively for reuse discharge. faster reordering, start important the year recovery period enhanced protocol, time, John. This by now clinical growth the clinicians, usage over to

Operator

That prepared call concludes Instructions] Butler We'll from remarks. to [Operator our questions. JMP the of question now Jason first your Securities. comes open Our

open. is line Your

Jason Butler

Hi, the for the thanks questions, the and taking launch. and on congrats progress

Gerri Henwood

Jason. Thanks,

Jason Butler

then, that the of color First follow-up. traction you're any interactions? only decisions new going have all, are where you're different of can of types having Thanks. where expected a impact would more of I having you to with a certain And the you the give just you're in? where terms and can what delaying have extent And institutions, to good pandemic give maybe us you in us product you and obvious of be quick getting institutions at virtual versus Thanks. sense

Gerri Henwood

Sure. Okay.

beginning launched versus delayed date, on the a XXth as make time April Well, plan, was sense, may March observations in decision the to have reps X. April, June. I'll the And our then to we of been? going have as not have of in made Where based to launched start like May on and the that where was start until them hiring original you are game we off. we might So recall,

we've months we're we of where from we there think month from a So pretty one skew would is close we're experience that, some few like early, be that. I the obviously out of impact, there. but Apart to thought in got

talk we're where of interactions aren't lot would working there tell the are of a I'll were to off us that John now of if face? But always virtual that the the going terms right even tells let some But we things of to how that. so we're And face in it of, faster. specifics is with happier way versus

John Harlow

as virtual it to Yes, Jason, good only. relates question

things, IDNs, it's the process. virtually where one we Our virtually agreement top done Vizient review whether right all are moving country virtually currently, the as done the with was announcement announcement a accounts well. haven't in that of starting but limited product as well the was disclosed we our as access more ordering of across having reps the XXX% seeing IDN, which the And that geographies bit the or the little the a using formulary product, initial in are direction, three

lead faster working, is strategy now of which use the to from predominantly formulary placements. reviews and right in majority believe our the coming outside ultimately Our formulary outpatient, is we will

Jason Butler

for patients, then data I just the or proposition expansions populations additional continue to thoughts uses? on the Gerri, of Okay, value label any presented great. bolster on looking ahead, thoughts these mentioned you you And new any preop value pursuing to the or guess, of need in work or clinical

Gerri Henwood

good focus launch. so is year on the this our supporting Obviously, Yes, questions.

more things substantially of well ongoing interesting successful And economics We trials done as which There like could could situations. providing some would very, like comfortable. house that are inquiries the in as use drug be flow from help things are and that Those being supporting clinicians involve and to that. way. a so, devoted coming outside in supply that considered. get to certainly launch described of think low to even We our are very different will publications, see here,

address or terms not number formal of this a in consultants of time, indicated of about of an think in or opportunity plans do label We management a labeling. our and the that some terms moderate-to-severe. for have in there's talking no outside label we're we things pain that In broad at more being expansion regulatory very evaluating whether wholesomely things to currently to moment

plan. evaluations a the part that penetrate could so be helpful? thoughts pretty and things that's a And in are Is of market. longer-term that of But there [indiscernible] that meantime, broad

Jason Butler

again Okay, on much. congrats that's progress. And very you the great. Thank

Gerri Henwood

Thanks very question, for much the Jason.

Operator

Piper from next Our of question comes Amsellem David Sandler.

open. line Your is

David Amsellem

thanks. Hey,

look usage So about your ASCs but usage we're mix sort maybe are these out and of get Thank to time. know – if losing where how know I on to steady it you that nothing, hospital between OFIRMEV days, how expect on but wanted over initially? just may early then exclusivity and evolve maybe thoughts to have over the get state ramifications hospitals another of on in longer-term say that thoughts ANJESO. the thinking think shake is wanted that what and do wanted for think or then the That's think you but procedures at one? but going about of you where exclusivity you. question, in to to which early number out? mix a shaking to long how And term that. ANJESO, going tissue. you ask similar of that versus loss number means your way, how J-code, about your words or procedure to mean, And have terms other is, lastly, mix basically think what mix, I hear the will adoption do OFIRMEV And have you you you bone any soft two you're the see of do

Gerri Henwood

Thanks. Sure. David. Thanks,

ask usage think to and of these mix at, So in we're now, to comments. two I'll of looking that location factors add right terms the of John I

separate at at hospital. surgeries, elective surgeries, themselves, look in they setting, easier in the we not COVID post to As are adopt

on perhaps feel hearing we're market to to a more don't patients but hearing, than have that about perhaps concerns formal comfortable research we're we warranted, that this, because hospital, an they I'm but So ASC have again, the environment. going

time be going our the and with a to are was formulary at of a in earlier. ASCs that's to strategy, And really independent little shorter bit generally consistent on coming based developed which where seems that so hospitals okays direction back patients

increase ASCs, a We've happy most, that We happening large happen the surgeries three towards but certainly those last urban be big we're changes run, percent they orthopedic reimbursing big joint that settings, think versus happening over outpatient XXXX, trend which I in the with We we're the cases in clustered in a of overnight, done years there for mean more. replacements to in as and in that, most part we’ll makes movement inpatient, think where mean we to think are the complex don't the continue setting So the to surgeries. long don't outpatient long of more run, surgical do in increase. CMS sense. is tends except that. And seen I

terms in in know see in I committees because a we want to little a priorities, getting to have from So bit We seem ultimate were be and the of hotspots think cases meetings. been those would away of hospital many mix, delayed formulary hospital. do desire. formulary the what be more We other taking They committee folks on track.

to which through. to hospital question? takes a part to the continue trial comments in add bit try to get expect is hope to you ASCs, way the the And advocacy the process that usage meantime for build want side. John, the we We any for and will it that quite time all of to a go get through And of process. that that in

John Harlow

Yes, from use I'll predominantly, we although that is obviously, other promising. coming seeing are add a is thing hospitals, of percentage our early David, ASCs, the which early from use is

of I to through agreement the few a we will surgeries a at pain the level orthopedic procedure and process well these as membership chronic go Gerri then mix still the pain contracts was not experts, at think alluding open lot standpoint, procedures, place, are ranging to with a there's to general of happening. early use. close although from reduced that because things a and as It's patients up as think well. which of procedures the been cost pain access lot with are interventional access procedural of some to a in formulary are different from Vizient provides lot in GPO hospital our These other that as Vizient We related pain product with elective procedures. a

promising. very we're which board, across the So, usage interesting early is and seeing

Gerri Henwood

that believe in – general we're In doing on targeting, and substantial well have reiterate, sort cost surgeons, us are natural intra-bdominal those surgery terms for to of that places areas. we And as surgeons David, orthopedic with anesthesiologists, more of colorectal. where benefit to we focus as data just

So that's part we're of of where we're seeing. not focused, that but areas the that's usage exclusive

of do to want OFIRMEV that? John, In loss of you speak terms to exclusivity,

John Harlow

obviously watching looking and very David, closely. Yes, this we're

We and research to market talk have customers. conducted some

that actually I last any used me will you obviously to acetaminophen first think the that week right. this appropriate reinforce. pain to continue together, it's said that's and pain should acute if assuming go a important something said the type. they true, be guidelines, we of that, guidelines, say That in is point patient And to customer NSAIDs

these research better can And outcomes. being can pain. that the I The other well with targeted heard users on of the as that market marketplace is, within dollars into other analgesics, they accounts, accounts EXPAREL. are branded spend treating available to if like thing OFIRMEV me for they've bigger is save we generic been on the again products dollars with approach multimodal that to that These of willing to we've are OFIRMEV had OFIRMEV IV as gives spend new and institutions, that see conversations I dollars branded provide including benefit because our the entries

not use the used just in accounts, think accounts, I a gives haven't more used haven't products reason it OFIRMEV we possible as in products. to branded them and this positive see So and those which branded

strategy targeting of ANJESO. down that really to in think our proposition and I the those come accounts believe value So David it'll

David Amsellem

Guys, thank you.

Gerri Henwood

David. Thanks,

John Harlow

David. Thanks,

Operator

Allred Our from question Oppenheimer. Trevor comes of next

open. is line Your

Trevor Allred

guys. for taking Thanks Hi, questions. my

Gerri Henwood

Sure.

Trevor Allred

ask rate to about formulary I just approvals for ANJESO. the of want

were turndown cases the and the So, those committee? it the where didn't get by what Thanks. in approved, for reasons

Gerri Henwood

Sure.

having sort hospitals formulary reason? getting of earlier, were just meetings targeted to of as primary specifically that to the what's you So, back schedule our to any had do a rejections not months up for in of been have the time, on present kind I But leading now number and And want the through we John, the that? mentioned speak fall.

John Harlow

good so question, Trevor. so, Yeah,

and As formularies. I said, over a ASCs between we and right have that XX have mix ANJESO It's accounts formulary hospitals now. on

preemptive have rejections been very had have single in We rejections some And the digits. low really those reviews.

to we information, within ANJESO communicate ability highlighted. going budget numbers buster where did institution some starting the oh a to very though the ANJESO as review right. of direction we see, is on formulary a sharing right. And an and IIIb see to and see data, Phase promising those – as share standpoint, boy that were able of be to areas the had to we that and So, small the Gerri In clinically, economically build and haven't they data relates again, ketorolac, they limited from this it both it value are the advocate

in the – that's advocates use I or advocate then had an have we was go not types everywhere, formulary to build – to of in in position whether that that digits. formulary not institution. future. really, able want product, colorectal were learning weeks also that and into to low procedures rejections But reviews able we this within think, and few approach it again, other procedures, I highlight been also very and orthopedic the more critical And appropriately were the the the discussion We last of as we've single procedures, had I'll for a we

Trevor Allred

great… All right,

Gerri Henwood

have quite September, October. number meetings out of look And scheduled a we we as August,

don't history the using products; many So if but have the growth because that substantial benefit do large but good a early continue we when hospitals info, that hope provide rounds targeting side strategy, number Again, we're that, cases, see of not a can data. other get better side. to the going you on these, end that to which to cost on to negative them, don't not we'll branded from we in have to to of even in look academic have our like possibly grow

those that often and going to prove to we're receptivity themselves. demonstrated desire it to think for arguments places a have I

Trevor Allred

Thanks. okay. It’s

Gerri Henwood

you. Thank

Operator

are we the further no turn to Now, showing Gerri questions. now I'll for closing remarks. back call

Gerri Henwood

and Thank future. you, care. the time safe having Take for all very and deployed a with enthused thank team day have this We're everyone you ANJESO and morning. launch the operator, wish we about happy that and us the for

Operator

gentlemen, conclude this does the and Ladies conference.

You may now disconnect.

Baudax Bio (BXRXQ) 10 Aug 202020 Q2 Earnings call transcript